Abstract:AbstractNearly one in six people worldwide suffer from disorders of the central nervous system (CNS). There is an urgent need for effective strategies to improve the success rates in CNS drug discovery and development. The lack of effective technologies for delivering drugs and genes to the brain due to the blood–brain barrier (BBB), a structural barrier that effectively blocks most neurotherapeutic agents from reaching the brain, has posed a formidable hurdle for CNS drug development. Brain‐homing and brain‐penetrating molecular transport vectors, such as brain permeable peptides or BBB shuttle peptides, have shown promise in overcoming the BBB and ferrying the drug molecules to the brain. The BBB shuttle peptides are discovered by phage display technology or derived from natural neurotropic proteins or certain viruses and harness the receptor‐mediated transcytosis molecular machinery for crossing the BBB. Brain permeable peptide–drug conjugates (PDCs), composed of BBB shuttle peptides, linkers, and drug molecules, have emerged as a promising CNS drug delivery system by taking advantage of the endogenous transcytosis mechanism and tricking the brain into allowing these bioactive molecules to pass the BBB. Here, we examine the latest development of brain‐penetrating peptide shuttles and brain‐permeable PDCs as molecular vectors to deliver small molecule drug payloads across the BBB to reach brain parenchyma. Emerging knowledge of the contribution of the peptides and their specific receptors expressed on the brain endothelial cells, choice of drug payloads, the design of PDCs, brain entry mechanisms, and delivery efficiency to the brain are highlighted.This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies Therapeutic Approaches and Drug Discovery > Nanomedicine for Neurological Disease

In vivo phage display screen for peptide sequences that cross the blood–cerebrospinal-fluid barrier

Identification of a peptide that crosses the blood-cerebrospinal fluid barrier by phage display technology

Identification of Peptide Sequences That Target to the Brain Using in Vivo Phage Display

Novel Blood–Brain Barrier Shuttle Peptides Discovered through the Phage Display Method

Specific Ligands for Classical Swine Fever Virus Screened from Landscape Phage Display Library.

Application of the phage display technology for the development of peptide-mediated drug delivery systems through the blood-brain barrier.

Identification of nose-to-brain homing peptide through phage display.

A Blood-Brain Barrier Crossing Peptide

Crossing the blood-brain-barrier with nanoligand drug carriers self-assembled from a phage display peptide

Phage-Displayed Peptide-Conjugated Biodegradable Nanoparticles Enhanced Brain Drug Delivery

Brain Penetrating Peptides and Peptide–drug Conjugates to Overcome the Blood–brain Barrier and Target CNS Diseases

Targeting The Brain With Peg-Plga Nanoparticles Modified With Phage-Displayed Peptides

In vivo phage display: identification of organ-specific peptides using deep sequencing and differential profiling across tissues

Screening On-Chip Fabricated Nanoparticles for Penetrating the Blood-Brain Barrier

Differential Blood-Brain Barrier Transport and Cell Uptake of Cyclic Peptides In Vivo and In Vitro

A blood-brain barrier and blood-brain tumor barrier penetrating peptide derived targeted therapeutics for glioma and malignant tumor brain metastases.

Blood-brain-barrier spheroids as an in vitro screening platform for brain-penetrating agents

Non-viral liposome-mediated transfer of brain-derived neurotrophic factor across the blood-brain barrier

Phage Display Generation of a Novel Humanized Single-Chain Antibody Against Brain Natriuretic Peptide with Potent Neutralizing Activity

Selection of LRP1 ligand phage-displayed single domain antibody that transmigrates BBB

Harnessing the capacity of cell-penetrating peptides for drug delivery to the central nervous system.